SURAKSHA Suraksha Diagnostic Q2 FY26 results (Jul–Sep 2025) and concall
Management summary
- Suraksha Diagnostic Limited reported strong revenue growth in Q2 and H1 FY26, driven by network expansion and sustained demand.
- However, profitability metrics like EBITDA and PAT margins were impacted in Q2 due to adverse weather conditions and early festivities.
- The company continues its strategic investment in new centers and genomics, expecting long-term margin expansion as these centers mature.
- Facing short-term pressure on realization per test due to discounts and B2B mix..
Source: Inve concall analysis and management guidance record.
Highlights
-
Total income for Q2 FY26 stood at INR79.58 crores, showing a growth of 16.9% year-on-year.
-
H1 FY26 revenue reached INR153.072 crores, marking a 17.8% year-over-year increase.
-
Network grew to 63 centers by the end of September 2025, including 3 new centers added in Q2 FY26.
-
Successfully launched Suraksha Genomics, a landmark event for advanced genetic and molecular testing services.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 59 | 64 | 70 | 76 |
| EBITDA | 18 | 20 | 24 | 24 |
| Net profit | 6 | 8 | 10 | 9 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Revenue Growth Revenue · FY26 · High confidence 15%
Profitability
EBITDA Margin Profitability · FY26 · High confidence 33% to 34%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Realization per test reduction Direct
So, this is because like you rightly mentioned, we do give discounts in the new centers that we set up to for traction of patients. That is one. And second is we have increased our B2B business, if you will see by 1%, and that normally consists of packages. Therefore, realization
Analyst questioned the decline in realization per test from INR389 to INR364, and management explained it was due to new center discounts and increased B2B business.
Asked by Mihir Singh
Increase in other expenses Direct
So normally, our other expenses as a percentage of sales, which ranges from 35% to 37%, 38%. So current quarter, we are at 40.5%. So, if you proportionately, if your sales -- if you consider the expenses, we have increased by around INR4 crores, the INR4 crores is mainly due to t
Analyst inquired about the INR4 crore increase in other expenses, and management provided a detailed breakdown, attributing it to rental expenses, professional fees to doctors, post-listing charges, and administrative expenses for new centers.
Asked by Mihir Singh
Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 8 risks, concerns & management red flags
- 5 watchlist triggers for Q3 FY26
- +9 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





